Drugs / N-hydroxy-nor-arginine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02009527 | Jan 2012 → Apr 2013 | coronary artery disorder, type 2 diabetes mellitus | Karolinska Institutet | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | N-hydroxy-nor-arginine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02009527 ↗ |
| Known as | Nω-hydroxy-nor-L-arginine | “during intra-arterial infusion of the arginase inhibitor (Nω-hydroxy-nor-L-arginine, 0.1 mg/min) or saline.” PMID 25072937 ↗ Jul 2014 |
| Route | Other | “during intra-arterial infusion of the arginase inhibitor (Nω-hydroxy-nor-L-arginine, 0.1 mg/min) or saline.” PMID 25072937 ↗ Jul 2014 |